Molecular structure of Tolcapone, CAS Number: 134308-13-7
Tolcapone (CAS 134308-13-7)
See product citations (1)
Alternate Names:
3,4-Dihydroxy-4′-methyl-5-nitrobenzophenone
Application:
Tolcapone is an inhibitor of peripheral and central catechol-O-methyltransferase
CAS Number:
134308-13-7
Purity:
≥97%
Molecular Weight:
273.24
Molecular Formula:
C14H11NO5
Supplemental Information:
This is as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Tolcapone serves as an inhibitor of the enzyme catechol-O-methyltransferase (COMT). By targeting COMT, Tolcapone effectively regulates the metabolism of dopamine, a neurotransmitter vital for movement and emotional regulation. Tolcapone operates as a reversible and competitive inhibitor of COMT, binding to its active site and preventing the enzyme from catalyzing the reaction between catecholamines and S-adenosylmethionine. By inhibiting COMT, Tolcapone elevates the levels of catecholamines, including dopamine, within the brain.
Tolcapone (CAS 134308-13-7) References
- Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. | Sant'Anna, R., et al. 2016. Nat Commun. 7: 10787. PMID: 26902880
- Comparison of the inhibitory effects of tolcapone and entacapone against human UDP-glucuronosyltransferases. | Lv, X., et al. 2016. Toxicol Appl Pharmacol. 301: 42-9. PMID: 27089846
- Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma. | Maser, T., et al. 2017. Cancer Med. 6: 1341-1352. PMID: 28429453
- The efficacy of homemade tolcapone in the treatment of patients with Parkinsons disease. | Zhang, PL., et al. 2018. Exp Ther Med. 15: 127-130. PMID: 29375679
- Effects of caspofungin, tolcapone and other FDA-approved medications on MRSA susceptibility to vancomycin. | Moore, JA., et al. 2020. J Glob Antimicrob Resist. 22: 283-289. PMID: 32247076
- Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. | Pinheiro, F., et al. 2021. FEBS J. 288: 310-324. PMID: 32324953
- Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses. | Qiu, M., et al. 2020. Front Microbiol. 11: 504. PMID: 32425892
- Interactions of tolcapone analogues as stabilizers of the amyloidogenic protein transthyretin. | Loconte, V., et al. 2020. Bioorg Chem. 103: 104144. PMID: 32791384
- Safety and efficacy of tolcapone in Parkinson's disease: systematic review. | Artusi, CA., et al. 2021. Eur J Clin Pharmacol. 77: 817-829. PMID: 33415500
- Pramipexole and tolcapone alleviate thermal and mechanical nociception in naive rats. | Mihaylova, A., et al. 2021. Folia Med (Plovdiv). 63: 377-384. PMID: 34196153
- How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements. | Agnieszka, W., et al. 2022. Curr Neuropharmacol. 20: 1427-1447. PMID: 34784871
- Tolcapone Derivative (Tol-D) Inhibits Aβ42 Fibrillogenesis and Ameliorates Aβ42-Induced Cytotoxicity and Cognitive Impairment. | Chen, B., et al. 2022. ACS Chem Neurosci. 13: 638-647. PMID: 35148068
- CSF/plasma levels, transthyretin stabilisation and safety of multiple doses of tolcapone in subjects with hereditary ATTR amyloidosis. | Takahashi, Y., et al. 2022. Amyloid. 29: 190-196. PMID: 35352593
- Micro- and Nano-Systems Developed for Tolcapone in Parkinson's Disease. | Casanova, Y., et al. 2022. Pharmaceutics. 14: PMID: 35631665
Inhibitor of:
ALDH1A3, ASPDH, COMT, DBH, ND1, NDUFB11, and NNT.Activator of:
AMPA 1, COMT, COMTD1, and D5DR.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tolcapone, 10 mg | sc-220266 | 10 mg | $167.00 |